Our best-in-class service platforms enable cell and gene therapies to be developed, manufactured, and released faster and with greater predictability
With decades of experience, WuXi Advanced Therapies’ provides a time-sensitive solution for production of high-quality Lentiviral vectors that meet your development timeline needs.
Our integrated single-source, in-house platform offers in-stock raw materials with established batch records, enhanced manufacturing scalability and flexibility, and complete testing capabilities.
- Industry-leading experience with robust scalability and consistent predictability.
- A honed two-tier development paradigm (EDP/LDP) with a closed system of end-to-end integrated solutions that speeds entry to the clinic.
- Dedicated process and analytical development teams to support feasibility studies and verification runs.
- A state-of-the-art GMP manufacturing facility – for both adherent and suspension production – that offers enhanced capacity and scheduling flexibility to meet customer timelines.
- Characterized MCB and WCB ready for client production and a secure supply with raw materials and consumables in stock – ready for use – with established batch records.
- Full in-process and release testing, plus complete quality control and characterization services with regulatory support.
- Consistent product quality and productivity when process is scaled up, and downstream process that typically results in 20-40% overall yield in viral particle.
- Multiple myeloma
- Danon disease
- Solid tumors
- Recessive Dystrophic Epidermolysis Bullosa (RDEB)
- B cell Non-Hodgkin Lymphoma
- Leukemia, lymphomas
- Feasibility; for CAR T
- Feasibility; solid cancer